Silo Pharma rises on promising results from pain disorder drug study

Silo Pharma

15/03/2023 13:53

** Shares of drug developer Silo Pharma Inc  SILO.O  rise
9.9% to $2.22 in morning trade
    ** Co says its experimental drug to treat fibromyalgia
showed positive results in a pre-clinical animal study
    ** Fibromyalgia is a chronic disorder that causes pain and
tenderness throughout the body, as well as fatigue and trouble
sleeping
    ** The study tested the drug candidate, SP-26, for
tolerability and any possible adverse effects - SILO
    ** SILO plans to prepare a Pre-Investigational New Drug
(IND) package for SP-26 and pursue regulatory pathway for drug
approval
    ** Including session's moves, SILO has tumbled ~73% in the
past 12 months

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))